UBROGEPANT ACHIEVE II RESULTS

Allergan™

Allergan Cautionary Statements

Forward Looking Statements

This communication includes statements that refer to estimated or anticipated future events and are forward looking statements. We have based our forward looking statements on management's beliefs and assumptions based on information available to our management at the time these statements are made. Such forward looking statements reflect our current perspective of our business, future performance, existing trends and information as of the date of this filing. These include, but are not limited to, our beliefs about future revenue and expense levels and growth rates, prospects related to our strategic initiatives and business strategies, including the integration of, and synergies associated with, strategic acquisitions, express or implied assumptions about government regulatory action or inaction, anticipated product approvals and launches, business initiatives and product development activities, assessments related to clinical trial results, product performance and competitive environment, and anticipated financial performance. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "plan," "intend," "could," "would," "should," "estimate," "continue," or "pursue," or the negative or other variations thereof or comparable terminology, are intended to identify forward looking statements. The statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions that are difficult to predict. We caution the reader that these statements are based on certain assumptions, risks and uncertainties, many of which are beyond our control. In addition, certain important factors may affect our actual operating results and could cause such results to differ materially from those expressed or implied by forward looking statements. These factors include, among others the inherent uncertainty associated with financial projections; the anticipated size of the markets and continued demand for Allergan's existing products; Allergan's ability to successfully develop and commercialize new products; Allergan's ability to conform to regulatory standards and receive requisite regulatory approvals; availability of raw materials and other key ingredients; uncertainty and costs of legal actions and government investigations; fluctuations in Allergan's operating results and financial condition, particularly given our manufacturing and sales of branded products; the impact of uncertainty around of timing of generic entry related to key products, including Restasis ®, on our financial results; risks associated with acquisitions, mergers and joint ventures, such as difficulties integrating businesses, uncertainty associated with financial projections, projected cost reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; expectations regarding contingent payments, including regarding litigation and related liabilities, purchase price adjustment or transaction consideration payments; the results of the ongoing business following the completion of the divestiture of Allergan's generics business to Teva; the adverse impact of substantial debt and other financial obligations on the ability to fulfill and/or refinance debt obligations; risks associated with relationships with employees, vendors or key customers as a result of acquisitions of businesses, technologies or products; our compliance with federal and state healthcare laws, including laws related to fraud, abuse, privacy security and others; generic product competition with our branded products; uncertainty associated with the development of commercially successful branded pharmaceutical products; costs and efforts to defend or enforce technology rights, patents or other intellectual property; expiration of patents on our branded products and the potential for increased competition from generic manufacturers; competition between branded and generic products; Allergan's ability to obtain and afford third-party licenses and proprietary technology we need; Allergan's potential infringement of others' proprietary rights; our dependency on third-party service providers and third-party manufacturers and suppliers that in some cases may be the only source of finished products or raw materials that we need; Allergan's competition with certain of our significant customers; the impact of our returns, allowance and chargeback policies on our future revenue; successful compliance with governmental regulations applicable to Allergan's and Allergan's respective third party providers' facilities, products and/or businesses; the difficulty of predicting the timing or outcome of product development efforts and regulatory agency approvals or actions, if any; Allergan's vulnerability to and ability to defend against product liability claims and obtain sufficient or any product liability insurance; Allergan's ability to retain qualified employees and key personnel; the effect of intangible assets and resulting impairment testing and impairment charges on our financial condition; Allergan's ability to obtain additional debt or raise additional equity on terms that are favorable to Allergan; difficulties or delays in manufacturing; our ability to manage environmental liabilities; global economic conditions; Allergan's ability to continue foreign operations in countries that have deteriorating political or diplomatic relationships with the United States; Allergan's ability to continue to maintain global operations and the exposure to the risks and challenges associated with conducting business internationally; risks associated with tax liabilities, or changes in U.S. federal or international tax laws to which we are subject, including the risk that the Internal Revenue Service disagrees that Allergan is a foreign corporation for U.S. federal tax purposes; risks of fluctuations in foreign currency exchange rates; risks associated with cyber-security and vulnerability of our information and employee, customer and business information that Allergan stores digitally; Allergan's ability to maintain internal control over financial reporting; changes in the laws and regulations, affecting among other things, availability, pricing and reimbursement of pharmaceutical products; the highly competitive nature of the pharmaceutical industry; Allergan's ability to successfully navigate consolidation of our distribution network and concentration of our customer base; the difficulty of predicting the timing or outcome of pending or future litigation or government investigations; developments regarding products once they have reached the market; risks related to Allergan's incorporation in Ireland, such as changes in Irish law and such other risks and other uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2017, and from time to time in Allergan's other investor communications. Except as expressly required by law, Allergan disclaims any intent or obligation to update or revise these forward-looking statements.

Disclaimer:

- This presentation is based on publicly available information
- These slides are intended for educational purposes only and for personal use of the audience
- The content of this slide deck is accurate to the best of the presenter's knowledge at the time of production

UNLABELED/UNAPPROVED USES DISCLOSURE:

This presentation includes investigational compound in development is not approved for treatment of acute migraine.

Summary: ACHIEVE II (UBR-MD-02) Met Both Co-Primary Regulatory Endpoints in ACHIEVE II at the 50mg Dose

- Ubrogepant met both registrational co-primary endpoints (pain freedom and absence of most bothersome symptom at 2 hours) at the 50 mg dose in ACHIEVE II
- Results were statistically significant and clinically meaningful across multiple outcome measures and highly consistent with results from ACHIEVE I
- Ubrogepant was well tolerated and demonstrated a hepatic safety profile similar to placebo with 3 cases of ALT or AST > 3X ULN vs 1 case on placebo. None of the cases were noted by the liver safety adjudication board to have a probable relationship to ubrogepant
- Ubrogepant 25 mg met the co-primary endpoint of pain freedom at 2 hours, but failed to demonstrate a statistically significant difference in the absence of the most bothersome migraine-associated symptom at 2 hours
- Allergan remains on track to file ubrogepant 25, 50, and 100 mg doses with the FDA in 1H 2019

ACHIEVE II Study Design



Co-primary Endpoints:	• 2 h pain free • 2 h absence of most bothersome symptom
Secondary Endpoints:	• 2 h pain relief • 2-24 h sustained pain relief • 2-24 h sustained pain free • 2 h absence of photophobia, phonophobia, and nausea

Highlights of ACHIEVE II Demographics – ITT Population

Parameter	Placebo (N=563)	Ubro 25mg (N=561)	Ubro 50mg (N=562)	Total (N=1686)
Age (years)				
Mean (SD)	41.5 (12.2)	41.6 (12.3)	41.0 (12.4)	41.4 (12.3)
Sex, n (%)				
Male	69 (12.3)	60 (10.7)	65 (11.6)	194 (11.5)
Female	494 (87.7)	501 (89.3)	497 (88.4)	1492 (88.5)
Race, n (%)				
White	449 (79.8)	467 (83.2)	456 (81.1)	1372 (81.4)
Black or African American	94 (16.7)	82 (14.6)	93 (16.5)	269 (16.0)
Ethnicity, n (%)				
Hispanic or Latino	116 (20.6)	129 (23.0)	125 (22.2)	370 (21.9)
Not Hispanic or Latino	447 (79.4)	432 (77.0)	437 (77.8)	1316 (78.1)

ACHIEVE II Met Co-primary Endpoints at the 50 mg Dose and Demonstrates Continued Efficacy Beyond 2 hours

Co-Primary Endpoints Met at the 50 mg Ubrogepant Dose

Endpoints	Statistics	Placebo (N=456)	Ubro 25mg (N=435)	Ubro 50mg (N=464)
Co-Primary Endpoint 1: *Pain Freedom 2 Hours After Initial Dose*	**Pain Free at 2 Hours, %**	**14.3**	**20.7**	**21.8**
	Adjusted p-value	**-**	***0.0285***	***0.0129***
Co-Primary Endpoint 2: *Absence of Most Bothersome Symptom[2] 2 Hours After Initial Dose*	**Absence of MBS[2], %**	**27.4**	**34.1**	**38.9**
	Adjusted p-value	**-**	***0.0711***	***0.0129***

Ubrogepant Demonstrates Continued Efficacy Beyond 2 Hours



(*) P-value < 0.0001, log-rank test comparing the 3 survival curves

Note: Modified ITT population only. 1. As compared to Placebo. 2. Most Bothersome Symptoms including Photophobia, Phonophobia or Nausea.

ACHIEVE II: Pain Freedom Benefit Increases Over Time



Note: Data are Kaplan-Meier estimates of pain freedom; mITT population

ACHIEVE II: Improved Benefit When Censoring Patients that Received Rescue Medication After 2 Hours

Non-censored data
(Modified ITT)

Kaplan-Meier Plot of Time to Pain Freedom Within 8 Hours of Initial Dose



(*) P-value < 0.0001, log-rank test comparing the 3 survival curves

Censored data
(no rescue, no second optional dose)

Kaplan-Meier Plot of Time to Pain Freedom Within 8 Hours of Initial Dose



(*) P-value < 0.0001, log-rank test comparing the 3 survival curves

ACHIEVE II: Pain Freedom Benefit Increases Over Time When Censoring Patients that Received Rescue Medication After 2 Hours



ACHIEVE I: Improved Benefit When Censoring Patients that Received Rescue Medication After 2 Hours

Non-censored data
(Modified ITT)

Kaplan-Meier Plot of Time to Pain Freedom Within 8 Hours of Initial Dose



(*) P-value < 0.0001, log-rank test comparing the 3 survival curves

Censored data
(no rescue, no second optional dose)

Kaplan-Meier Plot of Time to Pain Freedom Within 8 Hours of Initial Dose



(*) P-value < 0.0001, log-rank test comparing the 3 survival curves

Note: Modified ITT population only.

ACHIEVE I: Pain Freedom Benefit Increases Over Time When Censoring Patients that Received Rescue Medication After 2 Hours



Note: Data are Kaplan-Meier estimates of pain freedom; subjects were censored after taking rescue medication (including a second dose of IP)

ACHIEVE II: Ubrogepant Significantly Improved Pain Relief Over Placebo



(*) P-value < 0.0001, log-rank test comparing the 3 survival curves

ACHIEVE II: Safety/Tolerability Summary of Adverse Events

	Within 48 hours		
	Placebo (N=499) n (%)	Ubro 25mg (N=478) n (%)	Ubro 50mg (N=488) n (%)
Death	0	0	0
SAE	0	0	0
AE Discontinuation	0	0	0
Any TEAEs	51 (10.2)	44 (9.2)	63 (12.9)
Treatment-related TEAEs	30 (6.0)	30 (6.3)	42 (8.6)

	Within 30 days		
	Placebo (N=499) n (%)	Ubro 25mg (N=478) n (%)	Ubro 50mg (N=488) n (%)
Death	0	0	0
SAE	0	1 (0.2)	0
AE Discontinuation	0	0	0
Any TEAEs	112 (22.4)	105 (22.0)	133 (27.3)
Treatment-related TEAEs	39 (7.8)	34 (7.1)	54 (11.1)

ACHIEVE II: Safety/Tolerability Summary of Adverse Events

	Within 7 days		
ALT or AST	**Placebo (N=499)** n (%)	**Ubro 25mg (N=478)** n (%)	**Ubro 50mg (N=488)** n (%)
≥ 3x ULN	0	0	1/485 (0.2)
≥ 5x ULN	0	0	0
≥ 10x ULN	0	0	0
Potential Hy's Law (ALT or AST ≥3XULN and Bilirubin Total ≥ 2XULN and ALP < 2XULN)	0	0	0

	Within 30 days		
ALT or AST	**Placebo (N=499)** n (%)	**Ubro 25mg (N=478)** n (%)	**Ubro 50mg (N=488)** n (%)
≥ 3x ULN	1/493 (0.2)	0	3/485 (0.6)
≥ 5x ULN	0	0	0
≥ 10x ULN	0	0	0
Potential Hy's Law (ALT or AST ≥3XULN and Bilirubin Total ≥ 2XULN and ALP < 2XULN)	0	0	0

* In ACHIEVE I, within 7 days, one patient (0.02%) in the 50 mg arm had ALT/AST >3X ULN vs 0 in the 100 mg dose and 0 in the placebo group.

Conclusions: Ubrogepant Demonstrates Consistent Efficacy and Tolerability Across Both Pivotal Trials

- Ubrogepant met both registrational co-primary endpoints in ACHIEVE II at the 50mg dose
  - Pain Freedom at 2 hours
  - Absence of most bothersome symptoms at 2 hours
- Results were statistically significant and clinically meaningful across multiple outcome measures and highly consistent with results from ACHIEVE I
- Ubrogepant was very well tolerated and demonstrated an overall safety profile similar to placebo
- No signal of hepatotoxic effects was observed in ACHIEVE I or ACHIEVE II
- Allergan remains on track to file ubrogepant 25, 50, and 100 mg doses with the FDA in 1H 2019

UBROGEPANT ACHIEVE II RESULTS

Allergan™